Accelerate the development of your cardiovascular clinical program with scientific leadership, established site and KOL relationships, and full-service, integrated, global capabilities.
Accelerate the development of your cardiovascular clinical program with scientific leadership, established site and KOL relationships, and full-service, integrated, global capabilities.
Built on Cardiovascular Expertise: A Foundation in Cardiovascular Research
Cardiovascular research is part of our DNA at Medpace with more than 30 years of conducting Phase I–IV cardiovascular clinical trials. Medpace has developed a deep expertise managing complex cardiovascular studies which has shaped our scientific leadership, site relationships, and operational excellence needed to successfully accelerate cardiovascular programs – ranging from early-phase investigations to cardiovascular outcomes trials (CVOT).
Medpace’s integrated model brings together full-service CRO capabilities with central laboratories, bioanalytical services, ECG and imaging core laboratories, and a Phase I clinical pharmacology unit. This collaborative environment allows Sponsors to streamline development strategies, improve study efficiency, and generate high-quality clinical data.
Making the Complex Seamless® in Cardiovascular Clinical Development
Cardiovascular CRO Expertise
Medpace has extensive experience managing cardiovascular clinical trials across a broad range of indications and study types. Our global investigator relationships and deep therapeutic knowledge enable efficient execution of both specialized and large-scale cardiovascular studies.
Leveraging integrated clinical trial technology, centralized monitoring, and data-driven risk-based quality management, Medpace enhances study oversight, accelerates decision-making, and ensures consistent data quality across global programs. Our unified systems provide Sponsors with real-time visibility into trial performance, enabling proactive issue identification and streamlined execution.
Recognizing that cardiovascular disease frequently overlaps with other indications, our cardiovascular experts collaborate closely with other Medpace teams, such as nephrology, metabolic, and obesity research. This cross-therapeutic expertise enables a comprehensive approach to cardiometabolic clinical development.
Optimized Site Selection and Feasibility
Efficient site selection and patient recruitment are critical for cardiovascular trials, especially for large outcomes studies. Medpace combines data-driven feasibility with hands-on global site expertise to accelerate timelines and improve enrollment predictability.
Our IntelliPACE® Feasibility Platform integrates internal and external data to identify optimal countries and sites, ensuring access to high-performing investigators and relevant patient populations.
Site Relationship Coordinators serve as dedicated contacts for sites, providing tailored, country-specific support in local languages to expedite feasibility, start-up, and operational problem-solving.
The Medpace Flagship Site Program offers an established group of top performing global sites and site networks with a proven track record of delivering timely, quality outcomes. Aligning top-tier sites with Medpace’s rigorous standards ensures consistent support, rapid feasibility assessments, and efficient study start-up.
This combination of data-driven site selection and strong global site relationships helps Sponsors reduce recruitment delays, enhance data quality, and execute predictable, high-performing cardiovascular trials.
Comprehensive Laboratory Support
Cardiovascular drug development often relies on complex biomarker analysis and specialized laboratory testing. Medpace’s global central laboratories provide integrated scientific and operational support across the full spectrum of cardiovascular clinical development.
Our laboratories have supported hundreds of studies evaluating lipid-modifying therapies and cardiovascular risk biomarkers. Early collaboration with our PhD laboratory scientists helps Sponsors determine the most appropriate biomarkers and testing strategies to generate meaningful clinical insights while avoiding unnecessary testing.
Precise cardiovascular monitoring and endpoint evaluation are essential components of many clinical trials. Medpace’s cardiovascular core lab provides comprehensive cardiovascular monitoring capabilities for clinical trials optimized for over 30 years, routinely collaborating with the Medpace CRO on managed studies requiring central core lab services.
Medpace Core Lab Capabilities Include:
Centralized ECG acquisition and analysis
Advanced imaging support including CT, MR, ultrasound, and DXA
Centralized cardiac endpoint adjudication
Integration of wearable and remote monitoring devices
Cardiac Safety & Clinical Development Expertise
Early Phase Cardiac Safety & First-in-Human Studies
Cardiac safety evaluation is a critical component of early drug development. Medpace has extensive experience supporting first-in-human cardiovascular studies, as well as dedicated cardiac safety assessments including Thorough QT (TQT) studies conducted in accordance with ICH E14 regulatory guidelines.
With cardiac safety, clinical pharmacology, and operational teams integrated within a single organization, Medpace provides Sponsors with streamlined study start-up, consistent data collection, and high-quality ECG analysis.
Mid- to Late-Phase Cardiovascular Trials
Medpace has deep expertise in executing large, global cardiovascular outcomes programs, including complex and event-driven trials. Our experience includes adaptive trial designs, cardiovascular outcomes trials (CVOTs), and large-scale morbidity and mortality studies requiring precise endpoint adjudication and long-term follow-up.
“Having worked with Medpace for more than 25 years through the execution of cardiometabolic trials, what sets them apart from other Clinical Contract Research Organizations is their deep therapeutic experience, overwhelming positive site relationships, and their unique ability to be a tailored extension of the Sponsor team.
Whether supporting small biotech or larger pharma, from early-phase to large global late-phase studies, the Medpace team truly embody a partnership approach between Sponsor and CRO.”
John Kastelein, MD, PhD, FESC Chief Scientific Officer, NewAmsterdam Pharma
Cardiovascular Precision Medicine Program
Medpace’s Cardiovascular Precision Medicine Program brings together multidisciplinary experts with deep experience in cardiovascular biology, biomarker strategy, and targeted therapy development. These specialists work closely with Sponsors to design clinical trials focused on specific disease subphenotypes and molecular targets.
Medpace also supports the development of advanced therapies, including ATMPs and genetically modified products (GMOs), within cardiovascular indications. Our teams bring specialized regulatory expertise, established relationships with qualified investigational sites, and a strong understanding of the operational complexities associated with these. This ensures compliant, efficient execution of innovative and highly specialized cardiovascular studies.
